Botulinum-A toxin detrusor injections in the treatment of non-neurologic and neurologic cases of urge incontinence

Botulinum A toxin injections into the detrusor: An effective treatment in idiopathic and neurogenic detrusor overactivity?

“…Further studies are needed to determine if lower BTX-A doses will have the same bene¢cial e¡ects, while avoiding the need for intermittent selfcatheterization or other forms of urinary drainage. In the present study, the duration of the BTX-A e¡ect in idiopathic as well as in neurogenic detrusor overactivity was similar to that observed by Kuo [2004] but less than reported in other studies [Schurch et al, 2000a,b;Radziszewski and Borkowski, 2002;Schulte-Baukloh et al, 2002Chancellor et al, 2003;Loch et al, 2003;Riccabona et al, 2004;Schmid et al, 2004]. Although di¡erences in baseline characteristicsöespecially in the neurogenic group considering that our study included only two patients with spinal cord injury and none with myelomeningoceleömay be assumed, the exact reason for this phenomenon remains unclear.…”

Botulinum toxin and perineal disorders

“…Les études suivantes [20,21] ont confirmé l'efficacité de cette technique dans cette indication, avec des doses moindres que dans les vessies neurogènes (200 UI Botox ® en quarante sites) et avec environ 60 % d'amélioration (mais 20 % de rétention transitoire) évaluée sur des échelles de symptômes et de qualité de vie (UDI/IIQ). D'autres études sont désormais disponibles [22][23][24][25], faisant état de 80 % de succès clinique et urodynamique pour des doses allant de 100 à 300 UI Botox ® , avec des taux de rétention de 5 %.…”

Botulinum toxin for the treatment of lower urinary tract symptoms: A review

“…Radziszewski and Borkowski [2002] [abstract] reported that intradetrusal injections with botulinum toxin A 300 U [Dysport, Ipsen Ltd, Slough, Berkshire, UK; it is generally considered that 1 U of Botox is equivalent to 3^4 U of Dysport: Odergren et al, 1998], in 12 patients with IDO refractory to anticholinergics, improved symptoms such as frequency, urgency, and incontinence as well as increasing mean maximum cystometric capacity (321.2^408.3 ml). Similarly, Loch et al [2003] [abstract] has reported successful outcomes using an intradetrusal injection of 200 U (Botox, Allergan) in his series of patients with NDO and IDO with urge incontinence. Zermann et al [2001] [abstract] performed intradetrusal injections of the botulinum toxin A into the trigone of seven patients with urgency-frequency-syndrome refractory to anticholinergics.…”